AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Vaxcyte Inc (NASDAQ:PCVX)
32.23 USD
-5.530 14.645%Sponsored Reports
Loading...
| Previous Close (in USD) | 37.76 |
|---|---|
| Change | -5.530 14.645% |
| 52 W H/L (in USD) | 82.040/44.200 |
| EBITDA (in USD) | -507.878M |
| PE Ratio | -- |
| Volume | 8865703 |
| Diluted Eps TTM | -4.29 |
| Total Assets (in USD) | 1407.917M |
|---|---|
| Total Liabilities (in USD) | 167.449M |
| Revenue TTM (in USD) | -- |
| Cash (in USD) | 397.451M |
| Market Cap (in USD) | 7,474.216 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | -22.995M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Vaxcyte Inc
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Employees: 254
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Grant E. Pickering M.B.A. | Co-Founder, CEO & Director | 1968 |
| 2. | Mr. Andrew L. Guggenhime M.B.A. | Pres, CFO & Principal Accounting Officer | 1968 |
| 3. | Mr. James Wassil M.B.A., M.S. | Exec. VP & COO | 1969 |
| 4. | Mr. Paul W. Sauer M.B.A., MBA | Sr. VP of Process Devel. & Manufacturing | 1961 |
| 5. | Mr. Harp Dhaliwal M.B.A. | Sr. VP of Commercial Manufacturing & Supply Chain | 1973 |
| 6. | Dr. Ashish Khanna M.B.A., Ph.D. | Co-Founder and Chief Bus. Officer | 1972 |
| 7. | Dr. Jeff Fairman Ph.D. | Co-Founder & VP of Research | 1964 |
| 8. | Ms. Janet Graesser | VP of Corp. Communications & Investor Relations | NA |
| 9. | Mr. Mikhail Eydelman J.D. | Sr. VP, Gen. Counsel & Corp. Sec. | 1978 |
| 10. | Karen Alderete | Exec. Director of HR | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-1.410 2.031% | 69.98 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
0.000 0.000% | 68 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-0.080 0.017% | 486.27 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
-17.230 2.717% | 630.51 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -223.485M | -100.077M | -89.217M | -50.274M | -29.485M |
| Minority Interest | - | - | - | - | - |
| Net Income | -239.64M | -100.084M | -87.819M | -53.499M | -29.485M |
| Selling General Administrative | 39.81M | 25.259M | 16.017M | 8.546M | 5.388M |
| Gross Profit | - | - | - | - | - |
| Reconciled Depreciation | 9.196M | 3.457M | 1.405M | 1.232M | 1.037M |
| Ebit | -232.256M | -103.67M | -89.581M | -54.153M | -29.452M |
| Ebitda | -189.778M | -98.284M | -86.859M | -48.867M | -28.415M |
| Depreciation And Amortization | 42.478M | 5.386M | 2.722M | 5.286M | 1.037M |
| Operating Income | -232.256M | -103.67M | -89.581M | -54.153M | -35.533M |
| Other Operating Expenses | 207.33M | 102.085M | 87.103M | 53.916M | 35.533M |
| Interest Expense | 0.002M | 0.007M | 0.007M | 0.04M | 0.075M |
| Tax Provision | - | - | - | - | - |
| Interest Income | 8.356M | 0.344M | 0.244M | 0.632M | 0.903M |
| Net Interest Income | 8.354M | 0.337M | 0.237M | 0.592M | 0.828M |
| Income Tax Expense | 16.155M | 0.007M | -1.398M | 3.225M | 6.123M |
| Total Revenue | 0M | 0M | 0M | 0M | 0M |
| Total Operating Expenses | 207.33M | 102.085M | 87.103M | 53.916M | 35.533M |
| Cost Of Revenue | - | - | - | - | - |
| Total Other Income Expense Net | 8.771M | 3.593M | 0.364M | 3.879M | 5.22M |
| Net Income From Continuing Ops | -223.485M | -100.077M | -89.217M | -50.274M | -29.485M |
| Net Income Applicable To Common Shares | -223.485M | -100.077M | -89.217M | -50.274M | -29.485M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 1407.917M | 1006.178M | 324.337M | 392.826M | 65.698M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 12.12M | 11.179M | 10.378M | 2.804M | 2.747M |
| Total Liab | 167.449M | 52.565M | 40.319M | 46.983M | 172.071M |
| Total Stockholder Equity | 1240.468M | 953.613M | 284.018M | 345.843M | -106.373M |
| Other Current Liab | 123.638M | 24.82M | 16.682M | 17.076M | 7.515M |
| Common Stock | 0.098M | 0.082M | 0.056M | 0.054M | 0.007M |
| Capital Stock | 0.098M | 0.082M | 0.056M | 0.054M | 0.007M |
| Retained Earnings | -924.392M | -522.126M | -298.641M | -198.564M | -109.347M |
| Good Will | - | - | - | - | - |
| Other Assets | 0M | 5.426M | 4.96M | 0.55M | 0.584M |
| Cash | 397.451M | 834.657M | 68.985M | 386.2M | 58.976M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 145.338M | 40.525M | 28.716M | 46.861M | 11.052M |
| Current Deferred Revenue | - | - | - | - | - |
| Net Debt | -368.227M | -816.716M | -52.202M | -386.2M | -58.815M |
| Short Term Debt | 7.113M | 5.91M | 5.276M | - | 0.161M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 29.224M | 17.941M | 16.783M | - | 0.161M |
| Other Stockholder Equity | 2164.583M | 1476.018M | 258.507M | 544.353M | 2.967M |
| Property Plant Equipment | - | 31.648M | 35.912M | 3.272M | 3.391M |
| Total Current Assets | 1095.954M | 942.555M | 256.348M | 389.004M | 61.723M |
| Long Term Investments | 162.675M | 26.549M | 27.117M | - | - |
| Short Term Investments | 682.776M | 96.719M | 176.985M | - | - |
| Net Receivables | 3.607M | 1M | 1.2M | 0.3M | 0.2M |
| Long Term Debt | - | - | - | - | 0.45M |
| Inventory | - | - | - | - | - |
| Accounts Payable | 14.587M | 9.795M | 6.758M | 29.785M | 3.376M |
| Accumulated Other Comprehensive Income | 0.179M | -0.361M | -0.241M | -392.826M | -2.982M |
| Non Currrent Assets Other | 37.562M | 5.426M | 4.96M | 0.55M | 0.584M |
| Non Current Assets Total | 311.963M | 63.623M | 67.989M | 3.822M | 3.975M |
| Capital Lease Obligations | 29.224M | 17.941M | 16.783M | 0M | 0.161M |
| Long Term Debt Total | - | - | - | - | 0.45M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | 74.585M | -212.308M | -1.105M | -1.195M | -1.773M |
| Total Cashflows From Investing Activities | 74.585M | -212.308M | -1.105M | -1.195M | -1.773M |
| Total Cash From Financing Activities | 861.547M | 17.796M | 374.87M | 41.567M | 62.19M |
| Net Income | -223.485M | -100.077M | -89.217M | -50.274M | -29.485M |
| Change In Cash | 765.672M | -316.344M | 327.224M | -7.114M | 29.951M |
| Begin Period Cash Flow | 69.856M | 386.2M | 58.976M | 66.09M | 36.139M |
| End Period Cash Flow | 835.528M | 69.856M | 386.2M | 58.976M | 66.09M |
| Total Cash From Operating Activities | -170.597M | -121.393M | -46.628M | -47.145M | -30.466M |
| Depreciation | 9.196M | 3.457M | 1.405M | 1.232M | 1.037M |
| Other Cashflows From Investing Activities | - | 0.026M | 0.05M | - | 0.001M |
| Dividends Paid | - | - | -0.374M | - | - |
| Change To Inventory | - | - | - | 2.87M | -1.187M |
| Sale Purchase Of Stock | 1.033M | 0.888M | 0.374M | 42.942M | 62.473M |
| Other Cashflows From Financing Activities | 4.034M | 3.012M | 107.556M | 41.845M | 62.473M |
| Capital Expenditures | 5.848M | 6.555M | 1.155M | 1.195M | 1.774M |
| Change In Working Capital | 12.737M | -37.005M | 35.27M | 3.908M | 1.895M |
| Other Non Cash Items | 7.305M | 1.503M | 0.179M | -3.197M | -4.713M |
| Free Cash Flow | -176.445M | -127.948M | -47.783M | -48.34M | -32.24M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 11 months ago | 3066396 |
| 2. | American Funds SMALLCAP World A | 1 year ago | 2737778 |
| 3. | Vanguard Health Care Inv | 1 year ago | 2633933 |
| 4. | iShares Russell 2000 ETF | 11 months ago | 2477558 |
| 5. | Vanguard Small Cap Index | 11 months ago | 2469805 |
| 6. | Vanguard Institutional Extnd Mkt Idx Tr | 11 months ago | 1460494 |
| 7. | Fidelity Select Health Care | 1 year ago | 1450000 |
| 8. | Vanguard Small Cap Growth Index Inv | 11 months ago | 1394216 |
| 9. | Fidelity Growth Compy Commingled Pl O | 1 year ago | 1358348 |
| 10. | US Small-Cap Growth II Equity Comp | 1 year ago | 1230476 |
| 11. | T. Rowe Price New Horizons | 1 year ago | 1230476 |
| 12. | Janus Henderson US SMID Cap Growth | 1 year ago | 1219854 |
| 13. | Janus Henderson Triton D | 1 year ago | 1219854 |
| 14. | Fidelity Advisor Growth Opps M | 1 year ago | 1158643 |
| 15. | Fidelity Small Cap Index | 1 year ago | 1068928 |
| 16. | Fidelity Growth Company Fund | 1 year ago | 990916 |
| 17. | SPDR® S&P Biotech ETF | 11 months ago | 979549 |
| 18. | Fidelity Select Biotechnology | 1 year ago | 975180 |
| 19. | Janus Henderson Global Life Sciences D | 1 year ago | 933284 |
| 20. | Janus Henderson Global Life Sciences | 1 year ago | 933284 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Jennison Associates LLC | 1 year ago | 1256883 |
| 2. | FMR Inc | 1 year ago | 14213365 |
| 3. | Vanguard Group Inc | 1 year ago | 9737254 |
| 4. | BlackRock Inc | 1 year ago | 8575847 |
| 5. | RA Capital Management, LLC | 1 year ago | 7891254 |
| 6. | HHG PLC | 1 year ago | 7673868 |
| 7. | Wellington Management Company LLP | 1 year ago | 4431920 |
| 8. | Capital Research Global Investors | 1 year ago | 4140521 |
| 9. | T. Rowe Price Investment Management,Inc. | 1 year ago | 3552967 |
| 10. | State Street Corporation | 1 year ago | 3389528 |
| 11. | T. Rowe Price Associates, Inc. | 1 year ago | 3176181 |
| 12. | Geode Capital Management, LLC | 1 year ago | 1973506 |
| 13. | Perceptive Advisors LLC | 1 year ago | 1932759 |
| 14. | Driehaus Capital Management LLC | 1 year ago | 1867807 |
| 15. | AllianceBernstein L.P. | 1 year ago | 1780703 |
| 16. | Westfield Capital Management Company, LP | 1 year ago | 1586095 |
| 17. | Fred Alger Management, LLC | 1 year ago | 1396711 |
| 18. | BRAIDWELL LP | 1 year ago | 1212703 |
| 19. | COMMODORE CAPITAL LP | 1 year ago | 1100000 |
| 20. | Franklin Resources Inc | 1 year ago | 1076920 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Related Articles
Loading...
